Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974880 | 0.87 | ALDH1A1 (0.35) | SIGMAR1SMN1; SMN2ALDH1A1KDM4EEPHX1 | |
| SCHEMBL21183548 | 0.87 | EPHX2 (0.39) | SIGMAR1SMN1; SMN2ALDH1A1KDM4EEPHX1 | |
| SCHEMBL19975241 | 0.86 | EPHX1 (0.40) | SMN1; SMN2ALDH1A1TSHREPHX1 | |
| SCHEMBL19975106 | 0.86 | EPHX1 (0.40) | SMN1; SMN2ALDH1A1TSHREPHX1 | |
| SCHEMBL19975075 | 0.86 | USP2 (0.38) | SIGMAR1SMN1; SMN2ALDH1A1KDM4EEPHX1 | |
| SCHEMBL19974893 | 0.85 | BRD4 (0.33) | SMN1; SMN2KDM4EEPHX1 | |
| SCHEMBL21176384 | 0.82 | KDM4E (0.46) | SMN1; SMN2ALDH1A1KDM4EEPHX1HPGD | |
| SCHEMBL21176247 | 0.80 | KDM4E (0.48) | SMN1; SMN2ALDH1A1KDM4EEPHX1HPGD | |
| SCHEMBL19974993 | 0.79 | ALOX15 (0.44) | SIGMAR1SMN1; SMN2ALDH1A1TSHREPHX1 | |
| SCHEMBL19974996 | 0.79 | CTSD (0.38) | SMN1; SMN2ALDH1A1EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | SIGMAR1 1966/4885SMN1; SMN2 706/4885ALDH1A1 2271/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | SIGMAR1 2229/4885SMN1; SMN2 1086/4885ALDH1A1 2673/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | SIGMAR1 1966/4885SMN1; SMN2 706/4885ALDH1A1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.